The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes

3 September 2019 (10:05 - 10:55)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Arthur Mader

VIVIT Institute, Feldkirch (Austria)

6 More presentations in this session

Presentation thumbnail

Beta-blockers in diabetes with stable coronary heart disease- a cause for concern?

Assistant Professor A. Malik (Manchester, US)

Abstract Slides

Presentation thumbnail

Peripheral neuropathy and diastolic function are associated with adverse cardiovascular outcome in patients with type 1 diabetes mellitus: results from the thousand & 1 study

Doctor M. Jensen (Herlev, DK)

Presentation thumbnail

Heterogeneity of treatment effects from an intensive lifestyle weight loss intervention on cardiovascular events in patients with type 2 diabetes: data from the Look AHEAD trial.

Miss T. de Vries (Utrecht, NL)

Abstract Slides

Presentation thumbnail

Effects of the glucagon like peptide-1 receptor analogue, sodium-glucose co-transporter 2 and their combination on myocardial work index and vascular function in diabetes after 3-month treatment

Doctor I. Ikonomidis (Athens, GR)

Presentation thumbnail

Tissue sodium concentration emerged as a determinant of hypertrophic vascular remodeling in type 2 diabetes

Miss S. Jung (Erlangen, DE)

Abstract Slides

Access the full session

Session thumbnail

Diabetes and the heart

The Event

ESC Congress 2019

3 September 2019 10:05 CET

You may be interested in

Webinar

Biomarkers of clinical utility in cardiovascular disease

Congress Session

Challenges and innovations in cardiovascular risk stratification with cardiac biomarkers

Webinar

Personalised secondary prevention post-ACS: the role of biomarkers

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources